Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma |
| |
| Authors: | Katharina C Kaehler Vernon K Sondak Dirk Schadendorf Axel Hauschild |
| |
| Institution: | 1. Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada;2. Département de Médecine Nucléaire et de Radiobiologie, Université de Sherbrooke, Sherbrooke, QC, Canada;3. Department of Medical Imaging, University of Toronto, Toronto, ON, Canada;4. Toronto General Research Institute and Joint Department of Medical Imaging, University Health Network, Toronto, ON, Canada;1. Department of Dermatology, Center for Dermatooncology, University Medical Center Tübingen, Tübingen;2. Department of Dermatology and Allergy, Hannover Medical School, Hannover;3. Department of Dermatology, University Hospital Kiel, Kiel;4. Department of Dermatology, University Hospital Erlangen, Erlangen;5. Department of Dermatology, University Essen-Duisburg, Essen;6. Department of Dermatology, Hospital Dortmund, Dortmund;7. Department of Dermatology, Hospital Oldenburg, Oldenburg;8. Department of Dermatology, Charité Berlin, Berlin;9. Department of Dermatology, University Hospital Münster, Münster;10. Department of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;11. Department of Dermatology, University Hospital Graz, Graz, Austria;12. Department of Dermatology, University Hospital Leipzig, Leipzig, Germany;13. Department of Dermatology, AKH Wien, University Hospital Vienna, Vienna, Austria;14. Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt/Main;15. Department of Dermatology, Saarland University Medical School, Homburg/Saar;16. Department of Dermatology and Allergy, University Hospital of Munich, Munich, Germany;17. Assign Group, Innsbruck, Austria;1. Department of Physics and Astronomy, Uppsala University, Box 516, S-751 20 Uppsala, Sweden;2. Department of Engineering Sciences, Uppsala University, Box 534, S-751 21 Uppsala, Sweden |
| |
| Abstract: | Classic interferon-α formulations have antitumour activity in a variety of neoplastic diseases, including the adjuvant and palliative setting of metastatic melanoma, as single agents or in combination with chemotherapy and/or interleukin-2. Pegylated interferon, widely used for the treatment of hepatitis, seems to be at least equally efficacious as standard recombinant interferon in the treatment of metastatic melanoma, and the available evidence suggests that equi-efficacious doses have somewhat lower acute toxicity. Moreover, the favourable pharmacokinetic properties of pegylated interferon allow the administration on a weekly basis, with sustained exposure to interferon during that entire period.Several clinical trials have been conducted testing adjuvant and palliative treatment with pegylated interferon-α in high-risk melanoma patients with promising results. The role of pegylated interferons in the setting of advanced metastatic melanoma will need further investigation in clinical trials, potentially in combination with targeted or cytotoxic agents with regard to synergistic antiangiogenic and cytotoxic effects. The use of pegylated interferons in earlier stage melanomas will be investigated in upcoming trials. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
